A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer

被引：0
|
作者：
Vukelja, S.
Rugo, H.
Vogel, C.
Borson, R.
Tan-Chiu, E.
Birkner, M.
Holden, S. N.
Klencke, B.
O'Shaughnessy, J.
Burris, H. A.
机构：
[1] Tyler Canc Ctr, Tyler, TX USA
[2] UCSF Comprehens Canc Ctr, San Francisco, CA USA
[3] Lynn Canc Inst, Boca Raton, FL USA
[4] St Louis Canc & Breast Inst, St Louis, MO USA
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Baylor Sammons Canc Ctr, Dallas, TX USA
[7] Sarah Cannon Canc, Nashville, TN USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：71S / 71S
页数：1
相关论文
共 50 条
  • [31] A PHASE 2 STUDY OF TRASTUZUMAB EMTANSINE IN JAPANESE PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER
    Takahashi, S.
    Kashiwaba, M.
    Takao, S.
    Ito, Y.
    Doihara, H.
    Rai, Y.
    Matsubara, M.
    Kanatani, K.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 20 - 20
  • [32] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
    Parsons, Heather
    Ruddy, Kathryn
    Morganti, Stefania
    Smith, Karen
    Attaya, Victoria
    Kallfelz, Eliza
    DeMeo, Michelle
    LaScala, Jamie
    Mertz, Shirley
    Pollastro, Teri
    Spears, Patricia
    Brufsky, Adam
    Dang, Chau
    Dent, Susan
    Elkhanany, Ahmed
    Gwin, WIlliam
    O'Sullivan, Ciara
    Miller, Kathy
    Nunnery, Sara
    Walsh, Elaine
    Storniolo, Anna Maria
    Tolaney, Sara
    Tayob, Nabihah
    Wolff, Antonio
    Winer, Eric
    Rimawi, Mothaffar
    Krop, Ian
    Lin, Nancy
    CANCER RESEARCH, 2024, 84 (09)
  • [33] A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+breast cancer
    Krop, I. E.
    Mita, M.
    Burris, H. A.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Modi, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [34] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [35] Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
    Liang, Keying
    Mei, Shengsheng
    Gao, Xiangzheng
    Peng, Shanshan
    Zhan, Jinbiao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 5135 - 5150
  • [36] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [37] A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
    Zhao, Meng
    Pan, Xueliang
    Layman, Rachel
    Lustberg, Maryam B.
    Mrozek, Ewa
    Macrae, Erin R.
    Wesolowski, Robert
    Carothers, Sarah
    Puhalla, Shannon
    Shapiro, Charles L.
    Ramaswamy, Bhuvaneswari
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1285 - 1294
  • [38] A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
    Meng Zhao
    Xueliang Pan
    Rachel Layman
    Maryam B. Lustberg
    Ewa Mrozek
    Erin R. Macrae
    Robert Wesolowski
    Sarah Carothers
    Shannon Puhalla
    Charles L. Shapiro
    Bhuvaneswari Ramaswamy
    Investigational New Drugs, 2014, 32 : 1285 - 1294
  • [39] Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolo, Eleonora
    Repetto, Matteo
    Bielo, Luca Boscolo
    Tarantino, Paolo
    Curigliano, Giuseppe
    CANCER JOURNAL, 2022, 28 (06): : 436 - 445
  • [40] Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer
    Gajria, D.
    King, T.
    Pannu, H.
    Sakr, R.
    Modi, S.
    Drullinsky, P.
    Syldor, A.
    Path, S.
    Seidman, A.
    Norton, L.
    Rosen, N.
    Hudis, C.
    Chandarlapaty, S.
    CANCER RESEARCH, 2012, 72
12345